Gene: ABL1 ×
Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913451
rs121913451
ABL1
G 0.710 GeneticVariation CLINVAR Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: is that true for all the patients? 21605905

2011
dbSNP: rs121913459
rs121913459
ABL1
0.800 GeneticVariation BEFREE T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study. 16093432

2005
dbSNP: rs121913451
rs121913451
ABL1
A 0.710 GeneticVariation CLINVAR F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib. 21489624

2011
dbSNP: rs121913451
rs121913451
ABL1
G 0.710 GeneticVariation CLINVAR F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib. 21489624

2011
dbSNP: rs121913459
rs121913459
ABL1
0.800 GeneticVariation BEFREE A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia. 18587017

2008
dbSNP: rs121913455
rs121913455
ABL1
G 0.700 GeneticVariation CLINVAR A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib. 17008892

2006
dbSNP: rs121913459
rs121913459
ABL1
0.800 GeneticVariation BEFREE A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. 25127392

2014
dbSNP: rs121913459
rs121913459
ABL1
0.800 GeneticVariation BEFREE A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients. 21303525

2011
dbSNP: rs121913459
rs121913459
ABL1
0.800 GeneticVariation BEFREE AHI1 gene expression levels and BCR-ABL1 T315I mutations in chronic myeloid leukemia patients. 22183070

2011
dbSNP: rs121913459
rs121913459
ABL1
0.800 GeneticVariation BEFREE Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia. 26995693

2016
dbSNP: rs121913459
rs121913459
ABL1
0.800 GeneticVariation BEFREE Allogeneic transplantation remains an important therapeutic option for CML-CP harboring the T315I mutation, patients who fail 2nd generation TKIs, and for all patients in advanced phase disease. 23090888

2012
dbSNP: rs121913459
rs121913459
ABL1
0.800 GeneticVariation BEFREE Alternative strategies to specifically target T315I-BCR-ABL are needed for the treatment of CML patients harboring such a mutation. 29358661

2018
dbSNP: rs121913459
rs121913459
ABL1
0.800 GeneticVariation BEFREE Although, we continued to monitor bcr-abl transcripts in 14 CML patients (13 chronic phases and 1 accelerated phase) for up to 12 months, there were no patients who were apparently resistant to imatinib due to the T315I mutation. 19343480

2009
dbSNP: rs121913456
rs121913456
ABL1
G 0.710 GeneticVariation CLINVAR Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India. 21888027

2011
dbSNP: rs121913459
rs121913459
ABL1
0.800 GeneticVariation BEFREE ARDAP derivative <b>10</b> inhibited the proliferation of BCR/ABL-expressing KU812 and LAMA84 cells from chronic myeloid leukemia (CML) patients in blast crisis and of hematopoietic cells ectopically expressing the imatinib mesylate (IM)-sensitive KBM5-WT or its IM-resistant KBM5-T315I mutation. 28523104

2017
dbSNP: rs121913459
rs121913459
ABL1
0.800 GeneticVariation BEFREE Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients. 16038734

2005
dbSNP: rs121913457
rs121913457
ABL1
C 0.710 GeneticVariation CLINVAR Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML. 20607847

2010
dbSNP: rs121913459
rs121913459
ABL1
T 0.800 GeneticVariation CLINVAR BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. 11853795

2002
dbSNP: rs121913448
rs121913448
ABL1
A 0.730 GeneticVariation CLINVAR BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. 11853795

2002
dbSNP: rs121913449
rs121913449
ABL1
T 0.700 GeneticVariation CLINVAR BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. 11853795

2002
dbSNP: rs121913455
rs121913455
ABL1
G 0.700 GeneticVariation CLINVAR BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations? 21221851

2012
dbSNP: rs121913459
rs121913459
ABL1
T 0.800 GeneticVariation CLINVAR BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. 21562040

2011
dbSNP: rs121913452
rs121913452
ABL1
A 0.740 GeneticVariation CLINVAR BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. 21562040

2011
dbSNP: rs121913452
rs121913452
ABL1
C 0.740 GeneticVariation CLINVAR BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. 21562040

2011
dbSNP: rs1057519771
rs1057519771
ABL1
C 0.730 GeneticVariation CLINVAR BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. 21562040

2011